New combo therapy aims to wipe out stubborn myeloma cells

NCT ID NCT05497804

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of four drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) in 17 people with high-risk multiple myeloma. The goal is to see if the treatment can clear even tiny amounts of cancer left after initial therapy, known as minimal residual disease. Participants receive the drugs and undergo regular blood tests and bone marrow biopsies to track their response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib, daratumumab, lenalidomide, and dexamethasone
What this could lead to: If successful, this could lead to a more effective treatment strategy for high-risk multiple myeloma, potentially helping patients achieve longer remission.
What could go wrong: This is a small, early-phase trial with only 17 participants, so results may not apply to all patients. The drug combination also has known side effects like fatigue and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISS STAGE III PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISS STAGE III PLASMA CELL MYELOMA MULTIPLE MYELOMA

Contacts and locations

Locations

Mayo Clinic

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.